mirikizumab

Home
Ligands
mirikizumab

GtoPdb Ligand ID: 9846

Synonyms: Antibody I [US9023358] | LY-3074828 | LY3074828 | mirikizumab-mrkz | Omvoh®

mirikizumab is an approved drug (Japan, EMA and FDA (2023))

Comment: Mirikizumab (LY-3074828) is a humanized monoclonal antibody against human IL-23A (IL-23p19) which is designed for the treatment of autoimmune diseases. It is one of the novel agents for immune-mediated inflammatory diseases discussed in Baker et al. (2018) [1]. The peptide sequences of mirikizumab heavy and light chains are 100% matches to sequences 9 and 10 of Antibody I that is claimed in patent US9023358 [2].

Immunopharmacology Comments
Mirikizumab binds to IL-23A. This action reduces IL-23-mediated activation of Th17 cells, and inhibits their release of pro-inflammatory cytokines and chemokines.

Immunopharmacology Comments

Mirikizumab binds to IL-23A. This action reduces IL-23-mediated activation of Th17 cells, and inhibits their release of pro-inflammatory cytokines and chemokines.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Crohn's disease	Disease Ontology: DOID:8778 OMIM: 266600 Orphanet: ORPHA206	Phase 2 clinical candidate for active CD- see NCT02891226.
Psoriasis	Disease Ontology: DOID:8893	Phase 2 clinical candidate for moderate to severe plaque type psoriasis- see NCT02899988.
Ulcerative colitis	Disease Ontology: DOID:8577 OMIM: 266600 Orphanet: ORPHA771	Approved drug for moderate to severe UC	3